Fluconazole
Diflucan (fluconazole) is a small molecule pharmaceutical. Fluconazole was first approved as Diflucan on 1990-01-29. It is used to treat aids-related opportunistic infections, blastomycosis, chronic mucocutaneous candidiasis, coccidioidomycosis, and cryptococcal meningitis amongst others in the USA.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Diflucan (generic drugs available since 2004-07-29)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
diflucan | New Drug Application | 2022-06-24 |
fluconazole | ANDA | 2023-06-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
aids-related opportunistic infections | — | D017088 | — |
blastomycosis | EFO_0007174 | D001759 | B40 |
chronic mucocutaneous candidiasis | Orphanet_1334 | D002178 | B37.2 |
coccidioidomycosis | EFO_0007211 | D003047 | B38 |
cryptococcal meningitis | EFO_0007228 | D016919 | B45.1 |
fungemia | — | D016469 | B49 |
histoplasmosis | EFO_0007310 | D006660 | B39 |
mycoses | — | D009181 | B35-B49 |
oral candidiasis | EFO_0007406 | D002180 | B37.0 |
pneumonia | EFO_0003106 | D011014 | J18 |
Show 2 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AC: Imidazole and triazole derivatives, topical antifungals
— D01AC15: Fluconazole
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01R: Combinations of antibacterials
— J01RA: Combinations of antibacterials
— J01RA07: Azithromycin, fluconazole and secnidazole
— J02: Antimycotics for systemic use
— J02A: Antimycotics for systemic use
— J02AC: Triazole and tetrazole derivatives
— J02AC01: Fluconazole
HCPCS
Code | Description |
---|---|
J1450 | Injection fluconazole, 200 mg |
Clinical
Clinical Trials
199 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 4 | 6 | 2 | 23 | 37 |
Healthy volunteers/patients | — | 21 | 1 | — | 1 | 4 | 26 | ||
Cryptococcal meningitis | D016919 | EFO_0007228 | B45.1 | 1 | 6 | 3 | 1 | 18 | 26 |
Candidiasis | D002177 | B37 | 3 | 1 | 9 | 6 | 6 | 24 | |
Mycoses | D009181 | B35-B49 | 2 | 3 | 10 | 1 | 4 | 20 | |
Vulvovaginal candidiasis | D002181 | EFO_0007543 | B37.3 | 1 | 6 | 8 | 3 | — | 17 |
Oral candidiasis | D002180 | EFO_0007406 | B37.0 | — | 1 | 2 | 2 | 2 | 7 |
Fungemia | D016469 | B49 | — | 1 | 2 | 1 | — | 4 | |
Coccidioidomycosis | D003047 | EFO_0007211 | B38 | — | — | 1 | 1 | 1 | 3 |
Cryptococcosis | D003453 | EFO_0007229 | B45 | — | — | 1 | 1 | 1 | 3 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Candidemia | D058387 | EFO_1001282 | — | 2 | 7 | — | — | 9 | |
Invasive candidiasis | D058365 | EFO_1001283 | B37 | — | 2 | 6 | — | — | 8 |
Neoplasms | D009369 | C80 | 5 | — | 1 | — | — | 6 | |
Hiv | D006678 | O98.7 | — | 2 | 2 | — | — | 3 | |
Myeloid leukemia acute | D015470 | C92.0 | 1 | 1 | 1 | — | 1 | 3 | |
Lymphoma | D008223 | C85.9 | 2 | — | 1 | — | — | 3 | |
Leukemia | D007938 | C95 | — | — | 1 | — | 1 | 2 | |
Infections | D007239 | EFO_0000544 | — | 1 | 2 | — | — | 2 | |
Vaginitis | D014627 | EFO_0005757 | N76 | 1 | — | 1 | — | — | 2 |
Aspergillosis | D001228 | EFO_0007157 | B44 | — | — | 1 | — | 1 | 2 |
Show 21 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Crohn disease | D003424 | EFO_0000384 | K50 | — | 3 | — | — | — | 3 |
Stomatitis | D013280 | EFO_1001904 | K12.1 | — | 2 | — | — | — | 2 |
Meningitis | D008581 | EFO_0000584 | G03 | — | 1 | — | — | 1 | 2 |
Vulvovaginitis | D014848 | EFO_1001240 | N76.0 | — | 2 | — | — | — | 2 |
Sporotrichosis | D013174 | EFO_0007494 | B42 | — | 2 | — | — | — | 2 |
Histoplasmosis | D006660 | EFO_0007310 | B39 | — | 1 | — | — | 1 | 2 |
Nephrolithiasis | D053040 | N20.0 | — | 1 | — | — | — | 1 | |
Hypercalciuria | D053565 | R82.994 | — | 1 | — | — | — | 1 | |
Nephrocalcinosis | D009397 | HP_0000121 | — | 1 | — | — | — | 1 | |
Meningoencephalitis | D008590 | EFO_0007364 | A69.22 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Graft vs host disease | D006086 | D89.81 | 1 | — | — | — | 1 | 2 | |
Drug interactions | D004347 | 2 | — | — | — | — | 2 | ||
Therapeutic equivalency | D013810 | 2 | — | — | — | — | 2 | ||
Stem cell transplantation | D033581 | 1 | — | — | — | — | 1 | ||
Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 1 | — | — | — | — | 1 |
Prostatic neoplasms | D011471 | C61 | 1 | — | — | — | — | 1 | |
Endometriosis | D004715 | EFO_0001065 | N80 | 1 | — | — | — | — | 1 |
Mantle-cell lymphoma | D020522 | C83.1 | 1 | — | — | — | — | 1 | |
Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | — | — | — | — | 1 | |
Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
Cerebral hemorrhage | D002543 | — | — | — | — | 1 | 1 | ||
Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
Drug monitoring | D016903 | — | — | — | — | 1 | 1 | ||
Myelodysplastic syndromes | D009190 | D46 | — | — | — | — | 1 | 1 | |
Multiple myeloma | D009101 | C90.0 | — | — | — | — | 1 | 1 | |
Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
Hematopoietic stem cell transplantation | D018380 | — | — | — | — | 1 | 1 | ||
Bone marrow transplantation | D016026 | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | FLUCONAZOLE |
INN | fluconazole |
Description | Fluconazole is a member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis. It has a role as a P450 inhibitor, an environmental contaminant and a xenobiotic. It is a difluorobenzene, a conazole antifungal drug, a triazole antifungal drug and a tertiary alcohol. It is functionally related to a 1,3-difluorobenzene. It derives from a hydride of a 1H-1,2,4-triazole. |
Classification | Small molecule |
Drug class | systemic antifungals (miconazole type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F |
Identifiers
PDB | — |
CAS-ID | 86386-73-4 |
RxCUI | 4450 |
ChEMBL ID | CHEMBL106 |
ChEBI ID | 46081 |
PubChem CID | 3365 |
DrugBank | DB00196 |
UNII ID | 8VZV102JFY (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Diflucan - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 31,842 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more